Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 61 out of 100. Biomarkers

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Objective To develop, replicate, and validate an MRI-based quantitative measure of both cerebrovascular and neurodegeneration in Alzheimer disease (AD) for clinical and potentially research purposes. Methods We used data from a cross-sectional and longitudinal community-based study of Medicare-eligible residents in northern Manhattan followed every 18-24 months (n = 1,175, mean age 78 years). White matter hyperintensities, infarcts, hippocampal volumes, and cortical thicknesses were quantified from MRI and combined to generate an MRI measure associated with episodic memory. The combined MRI measure was replicated and validated using autopsy data, clinical diagnoses, and CSF biomarkers and amyloid PET from the Alzheimer's Disease Neuroimaging Initiative. Results The quantitative MRI measure was developed in a group of community participants (n = 690) and replicated in a similar second group (n = 485). Compared with healthy controls, the quantitative MRI measure was lower in patients with mild cognitive impairment and lower still in those with clinically diagnosed AD. The quantitative MRI measure correlated with neurofibrillary tangles, neuronal loss, atrophy, and infarcts at postmortem in an autopsy subset and was also associated with PET amyloid imaging and CSF levels of total tau, phosphorylated tau, and β-amyloid 42. The MRI measure predicted conversion to MCI and clinical AD among healthy controls. Conclusion We developed, replicated, and validated an MRI measure of cerebrovascular and neurodegenerative pathologies that are associated with clinical and neuropathologic diagnosis of AD and related to established biomarkers.

What this study adds

Evidence grade: Moderate

This is a cross-sectional study of 1,175 participants. This study developed and validated an MRI-based measure combining cerebrovascular and neurodegenerative features that was lower in people with mild cognitive impairment and Alzheimer's disease and predicted conversion to these conditions. It is a diagnostic and research tool and does not report any treatment, cure, or prevention of Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Brickman, A. M., Tosto, G., Gutierrez, J., Andrews, H., Gu, Y., Narkhede, A., et al. (2018). An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease. Neurology. https://doi.org/10.1212/wnl.0000000000006310

Vancouver

Brickman AM, Tosto G, Gutierrez J, Andrews H, Gu Y, Narkhede A, et al. An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease. Neurology. 2018. doi:10.1212/wnl.0000000000006310. PMID: 30217936.

BibTeX

@article{brickman2018-30217936,
  author  = {Brickman, A. M. and Tosto, G. and Gutierrez, J. and Andrews, H. and Gu, Y. and Narkhede, A. and Rizvi, B. and Guzman, V. and others},
  title   = {{An MRI measure of degenerative and cerebrovascular pathology in Alzheimer disease}},
  journal = {Neurology},
  year    = {2018},
  doi     = {10.1212/wnl.0000000000006310},
  pmid    = {30217936},
  url     = {https://doi.org/10.1212/wnl.0000000000006310}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This study developed and validated an MRI-based measure combining cerebrovascular and neurodegenerative features that was lower in people with mild cognitive impairment and Alzheimer's disease and predicted conversion to these conditions. It is a diagnostic and research tool and does not report any treatment, cure, or prevention of Alzheimer's disease.

Study details

How this study scored 61/100
How this study's score is builtJournal tier 9 of 10; Journal's citation record 4 of 4; Study design 4 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 4 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 2 of 6; Still being cited 2 of 4; Senior author's track record 4 of 4; Institution's track record left out, no data; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. 59 of the 97 points it could be judged on, which is 61 of 100. Total 61 of 100.59 of the 97 points we could judge = 61 of 100

Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 59 of the 97 points we could judge it on, which is 61 out of 100.

ComponentPointsWhy
Journal tier 9 / 10 Tier 2 — leading specialty journal (Neurology)
Journal's citation record 4 / 4 Neurology: journal h-index 525 (OpenAlex, 2026-10-29)
Study design 4 / 12 A snapshot of people at one point in time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2018 — within 10 year(s) of the newest study here
Sample size 3 / 4 1,175 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 4 / 7 Cited 74 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 7.4 citations a year over 10 year(s) since 2018
Impact for its field and year 3 / 6 Cited 6.8× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 2 / 6 Cited by 4 other studies in this library
Still being cited 2 / 4 Cited 22 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Richard P Mayeux: h-index 158 (OpenAlex, whole career)
Institution's track record — / 3 No institution listed in OpenAlex — left out of this score
Multicenter collaboration 2 / 3 PubMed indexes it as a multicentre study
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 30217936)
Free to read 0 / 2 Behind a paywall — scores zero
Points 59 / 97 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 97 points we could judge it on is 61 out of 100.
Total 61 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 23.

Later studies that cite this one

4 studies in the alzhub library list this one in their references.

Related studies in Biomarkers from nearby years

Also tagged “machine”

834 studies in the library carry the topic tag “machine”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 834 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Biomarkers

See all studies in Biomarkers →